Biophytis launches €9m Nasdaq IPO Biophytis has priced its IPO on Nasdaq Paris. The company aims to raise up to €10.8m to advance its lead drug candidate under development for the treatment of neuromuscular diseases. more ➔
€30m for Evotec cancer spin-outGerman biotech group Evotec has once more launched a spin-off: Breakpoint Therapeutics GmbH is focusing on treating cancer patients by targeting DNA damage responses. more ➔
Partnership in pursuit of new antibiotics...A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German drug discovery company Evotec SE to develop a novel … more ➔
Drug puts CAR T activity on hold German researchers have found a way to curb the activity of CAR T cells, even while keeping their cancer-fighting properties intact. more ➔
License deal in oncolytic virotherapiesOncovita has been granted the exclusive license to an immuno-oncolytic measles virus platform developed by the Institut Pasteur. Based on the technology, the Paris-based biotech plans to develop cancer … more ➔
Boehringer Ingelheim and Yuhan Corp. in US...Boehringer Ingelheim has licenced a preclinical fusion protein from Korean Yuhan Corp. that activates both GLP-1R and FGF21R to treat Nonalcoholic Steatohepatitis (NASH). Boehringer Ingelheim will pay … more ➔
Smart bra set to detect breast cancerA French-Swiss research team is developing a smart bra for detecting breast cancer more accessible than through mammography. more ➔
GARDP wants five AMR breakers by 2025GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025. more ➔
Sanifit raise €72.2m to push SNF472 deve...Sanifit has bagged €72.2m in Spain’s largest private biotech fundraise. more ➔
Genfit in $228m deal with Terns Pharmaceut...Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.   … more ➔
